thalidomide has been researched along with Hypesthesia in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hypesthesia: Absent or reduced sensitivity to cutaneous stimulation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized, placebo-controlled, double-blind trial, thalidomide or placebo together with glucocorticoids and either cyclosporine or tacrolimus was administered as initial therapy for clinical extensive chronic graft-versus-host disease (cGVHD)." | 9.09 | Thalidomide for treatment of patients with chronic graft-versus-host disease. ( Anasetti, C; Appelbaum, FR; Deeg, HJ; Flowers, ME; Koc, S; Leisenring, W; Martin, PJ; Nash, RA; Sanders, JE; Storb, R; Witherspoon, RP, 2000) |
| "The aim of this study was to define prognostic factors that might be predictive for response to thalidomide (Thal) in progressive multiple myeloma (n = 54)." | 9.09 | High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Hillengass, J; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2001) |
| "Factors that affect the response of multiple myeloma patients to thalidomide were evaluated in 40 patients who were not eligible for chemotherapy (untreated: 14, relapse/refractory: 26)." | 7.76 | [Factors affecting the response of thalidomide therapy for patients with multiple myeloma]. ( Agata, M; Ishiyama, M; Kazama, H; Kondo, T; Mori, N; Motoji, T; Oda, T; Okamura, T; Sagawa, K; Sameshima, Y; Shiseki, M; Teramura, M; Yamada, O; Yasunami, T; Yoshinaga, K, 2010) |
| "In a randomized, placebo-controlled, double-blind trial, thalidomide or placebo together with glucocorticoids and either cyclosporine or tacrolimus was administered as initial therapy for clinical extensive chronic graft-versus-host disease (cGVHD)." | 5.09 | Thalidomide for treatment of patients with chronic graft-versus-host disease. ( Anasetti, C; Appelbaum, FR; Deeg, HJ; Flowers, ME; Koc, S; Leisenring, W; Martin, PJ; Nash, RA; Sanders, JE; Storb, R; Witherspoon, RP, 2000) |
| "The aim of this study was to define prognostic factors that might be predictive for response to thalidomide (Thal) in progressive multiple myeloma (n = 54)." | 5.09 | High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Hillengass, J; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2001) |
| "Factors that affect the response of multiple myeloma patients to thalidomide were evaluated in 40 patients who were not eligible for chemotherapy (untreated: 14, relapse/refractory: 26)." | 3.76 | [Factors affecting the response of thalidomide therapy for patients with multiple myeloma]. ( Agata, M; Ishiyama, M; Kazama, H; Kondo, T; Mori, N; Motoji, T; Oda, T; Okamura, T; Sagawa, K; Sameshima, Y; Shiseki, M; Teramura, M; Yamada, O; Yasunami, T; Yoshinaga, K, 2010) |
| "Thalidomide was administered as a therapeutic agent for chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in a patient with breast cancer." | 3.69 | Thalidomide-induced perioral neuropathy. ( Elad, S; Galili, D; Garfunkel, AA; Or, R, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agata, M | 1 |
| Sameshima, Y | 1 |
| Oda, T | 1 |
| Kondo, T | 1 |
| Ishiyama, M | 1 |
| Yasunami, T | 1 |
| Kazama, H | 1 |
| Okamura, T | 1 |
| Yoshinaga, K | 1 |
| Shiseki, M | 1 |
| Mori, N | 1 |
| Yamada, O | 1 |
| Sagawa, K | 1 |
| Teramura, M | 1 |
| Motoji, T | 1 |
| Xu, JT | 1 |
| Xin, WJ | 1 |
| Wei, XH | 1 |
| Wu, CY | 1 |
| Ge, YX | 1 |
| Liu, YL | 1 |
| Zang, Y | 1 |
| Zhang, T | 1 |
| Li, YY | 1 |
| Liu, XG | 1 |
| Elad, S | 1 |
| Galili, D | 1 |
| Garfunkel, AA | 1 |
| Or, R | 1 |
| Koc, S | 1 |
| Leisenring, W | 1 |
| Flowers, ME | 1 |
| Anasetti, C | 1 |
| Deeg, HJ | 1 |
| Nash, RA | 1 |
| Sanders, JE | 1 |
| Witherspoon, RP | 1 |
| Appelbaum, FR | 1 |
| Storb, R | 1 |
| Martin, PJ | 1 |
| Neben, K | 1 |
| Moehler, T | 1 |
| Egerer, G | 1 |
| Kraemer, A | 1 |
| Hillengass, J | 1 |
| Benner, A | 1 |
| Ho, AD | 1 |
| Goldschmidt, H | 1 |
| Sabin, TD | 1 |
2 trials available for thalidomide and Hypesthesia
| Article | Year |
|---|---|
Thalidomide for treatment of patients with chronic graft-versus-host disease.
Topics: Actuarial Analysis; Chronic Disease; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; G | 2000 |
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Topics: Adult; Affect; Aged; Angiogenesis Inhibitors; Constipation; Dizziness; Dose-Response Relationship, D | 2001 |
4 other studies available for thalidomide and Hypesthesia
| Article | Year |
|---|---|
[Factors affecting the response of thalidomide therapy for patients with multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Constipation; Dexamethasone; Disease-Free Survival; Drug Eruptions; | 2010 |
p38 activation in uninjured primary afferent neurons and in spinal microglia contributes to the development of neuropathic pain induced by selective motor fiber injury.
Topics: Animals; Denervation; Enzyme Activation; Enzyme Inhibitors; Ganglia, Spinal; Hyperalgesia; Hypesthes | 2007 |
Thalidomide-induced perioral neuropathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adju | 1997 |
Letter: Thalidomine neuropathy and leprous neuritis.
Topics: Diagnosis, Differential; Humans; Hypesthesia; Leprosy; Mycobacterium leprae; Neuritis; Peripheral Ne | 1974 |